WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the
– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment,
– Company reports record demand for YCANTH® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year – – Topline data from global Phase 3 program studying
— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations — — Facility provides potential for no scheduled interest or principal payments
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCANTH for
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica")
